Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + Cemiplimab + Chemotherapy in First-Line Advanced NSCLC
NCT05800015Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Jan 2030
- Countries
- 10
01
Overview
A Phase 3 trial of fianlimab in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Aug 2023; status: active, not recruiting.
02
Drugs
fianlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05800015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800015.